Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Gail J. Roboz, Guillermo Sanz, Elizabeth A. Griffiths, Karen Yee, Hagop Kantarjian, Christian Récher, Michael T. Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L. O'Connell, Yong Hao, Harold N. Keer, Mohammad Azab, Hartmut Döhner

Open source

DOI: 10.1182/bloodadvances.2023012062
Published: 2024-04-23
Container: Blood Advances
Publisher: American Society of Hematology
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2023012062,
  title = {Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial},
  author = {Gail J. Roboz and Guillermo Sanz and Elizabeth A. Griffiths and Karen Yee and Hagop Kantarjian and Christian Récher and Michael T. Byrne and Elżbieta Patkowska and Hee-Je Kim and Xavier Thomas and Ine Moors and Wendy Stock and Árpád Illés and Pierre Fenaux and Yasushi Miyazaki and Takahiro Yamauchi and Casey L. O'Connell and Yong Hao and Harold N. Keer and Mohammad Azab and Hartmut Döhner},
  year = {2024},
  journal = {Blood Advances},
  doi = {10.1182/bloodadvances.2023012062},
  url = {https://doi.org/10.1182/bloodadvances.2023012062}
}

RIS

TY  - JOUR
TI  - Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial
AU  - Gail J. Roboz
AU  - Guillermo Sanz
AU  - Elizabeth A. Griffiths
AU  - Karen Yee
AU  - Hagop Kantarjian
AU  - Christian Récher
AU  - Michael T. Byrne
AU  - Elżbieta Patkowska
AU  - Hee-Je Kim
AU  - Xavier Thomas
AU  - Ine Moors
AU  - Wendy Stock
AU  - Árpád Illés
AU  - Pierre Fenaux
AU  - Yasushi Miyazaki
AU  - Takahiro Yamauchi
AU  - Casey L. O'Connell
AU  - Yong Hao
AU  - Harold N. Keer
AU  - Mohammad Azab
AU  - Hartmut Döhner
PY  - 2024
JO  - Blood Advances
DO  - 10.1182/bloodadvances.2023012062
UR  - https://doi.org/10.1182/bloodadvances.2023012062
ER  -

APA

Roboz, G. J., Sanz, G., Griffiths, E. A., Yee, K., Kantarjian, H., Récher, C., Byrne, M. T., Patkowska, E., Kim, H., Thomas, X., Moors, I., Stock, W., Illés, Á., Fenaux, P., Miyazaki, Y., Yamauchi, T., O'Connell, C. L., Hao, Y., Keer, H. N., Azab, M., & Döhner, H. (2024). Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood Advances. https://doi.org/10.1182/bloodadvances.2023012062

Source records

crossref · retrieved 2026-09-26T12:39:48.117Z